Figure 1
Hypomethylation of OAS2 in psoriasis and SCCHN.
(a) Schematic diagram of CpG sites spans −500 bp upstream of transcription start site (TSS) to the first exon (+317 bp). CpG sites are indicated by vertical ticks. The CpG sites covered by PyroMark CpG assays are numbered in order from 1 to 11 (pyrosequencing ID). Array identified hypomethylated CpG sites in psoriasis are highlighted by thick vertical ticks. (b–d) Methylation status of 11 CpG sites in psoriasis, tongue SCC and tonsillar SCC determined by pyrosequencing analysis. Individual methylation data are shown as dot plots and the horizontal lines indicate means. Mean methylation difference (MMD) between disease and controls is shown under each CpG sites. Mann-Whitney U test was performed for comparing psoriasis with controls and Wilcoxon signed ranks test for comparing tumour with adjacent tumour-free samples (***P < 0.001, **P < 0.01, *P < 0.5).
